5 employees
Phialogics is focuses on developing next-generation biologics to balance the immune response in both acute and long-term inflammation.
2021
$656K
from 1 investors over 1 rounds
Phialogics - The immune tolerance company raised $656K on April 19, 2023
Investors: High-Tech Gründerfonds